search
Back to results

Budd-Chiari Syndrome in China: Balloon Angioplasty Alone or Combined With Stent Placement?

Primary Purpose

Budd-Chiari Syndrome

Status
Completed
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Stent
Balloon
Sponsored by
Air Force Military Medical University, China
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Budd-Chiari Syndrome focused on measuring Budd-Chiari syndrome, percutaneous recanalization, treatment, reocclusion, patency

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Informed consent.
  2. Age 18-75 years old.
  3. Budd-Chiari syndrome
  4. Child-Pugh score <13 points.
  5. Eligible for percutaneous recanalization.

Exclusion Criteria:

  1. Pregnancy or lactation.
  2. Malignancy.
  3. HIV infection.
  4. Severe cardiac or lung diseases.
  5. Severe renal dysfunction (serum> 265.2 umol/l).
  6. Uncontrolled systemic infection.
  7. Allergic to contrast agents.
  8. Poor compliance.
  9. A prior history of percutaneous recanalization.
  10. Ineligible for percutaneous recanalization.
  11. Liver cirrhosis with severe portal hypertension-related complications.
  12. Acute liver failure.
  13. Progressive deterioration of liver function.

Sites / Locations

  • Xijing Hospital of Digestive Diseases

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

PTA in combination with stent-placement

PTA alone

Arm Description

In this group, the patients will undergo percutaneous balloon angioplasty with or without stent-placement angioplasty in combination with stent-placement.

In this group, the patients will undergo percutaneous balloon angioplasty alone. The patients will transfer to the stent placement in the following cases: 1) reocclusion with thrombosis; and 2) at least 2 reocclusion events.

Outcomes

Primary Outcome Measures

The incidence of reocclusion between PTA alone and in combination with stent-placement groups

Secondary Outcome Measures

The survival between PTA alone and in combination with stent placement groups
The incidence of procedure-related complications between PTA alone and in combination with stent placement groups
The length of hospitalization between PTA alone and in combination with stent placement groups
The symptom recurrence rate between PTA alone and in combination with stent placement groups

Full Information

First Posted
July 24, 2014
Last Updated
April 20, 2019
Sponsor
Air Force Military Medical University, China
search

1. Study Identification

Unique Protocol Identification Number
NCT02201485
Brief Title
Budd-Chiari Syndrome in China: Balloon Angioplasty Alone or Combined With Stent Placement?
Official Title
Balloon Angioplasty Alone Versus in Combination With Stent Placement for the Treatment of Budd-Chiari Syndrome in China: An Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
April 2019
Overall Recruitment Status
Completed
Study Start Date
May 2014 (undefined)
Primary Completion Date
September 2017 (Actual)
Study Completion Date
April 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Air Force Military Medical University, China

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Budd-Chiari syndrome (BCS) is defined as the hepatic outflow obstruction from the small hepatic veins to the confluence between inferior vena cava and right atrium, which often leads to the life-threatening complications, such as liver failure and portal hypertension-related complications. At present, a stepwise treatment strategy is employed, including anticoagulation, thrombolysis, percutaneous recanalization (i.e., percutaneous transluminal angioplasty [PTA] alone or in combination with stent placement), transjugular intrahepatic portosystemic shunt, and liver transplantation. In West, only less than 20% of BCS patients underwent percutaneous recanalization; by contrast, percutaneous recanalization is the most common treatment modality used in China. Recently, an 11-year retrospective case series of 177 Chinese patients with primary BCS has shown a higher rate of re-occlusion in the PTA alone group than in the PTA combined with stent placement group (31% versus 7.7%, p<0.001). In addition, re-occlusion was regarded as the independent predictor of mortality. Accordingly, we hypothesized that PTA alone might have a worse survival than PTA combined with stent placement in Chinese patients with primary BCS.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Budd-Chiari Syndrome
Keywords
Budd-Chiari syndrome, percutaneous recanalization, treatment, reocclusion, patency

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Care Provider
Allocation
Randomized
Enrollment
88 (Actual)

8. Arms, Groups, and Interventions

Arm Title
PTA in combination with stent-placement
Arm Type
Active Comparator
Arm Description
In this group, the patients will undergo percutaneous balloon angioplasty with or without stent-placement angioplasty in combination with stent-placement.
Arm Title
PTA alone
Arm Type
Active Comparator
Arm Description
In this group, the patients will undergo percutaneous balloon angioplasty alone. The patients will transfer to the stent placement in the following cases: 1) reocclusion with thrombosis; and 2) at least 2 reocclusion events.
Intervention Type
Device
Intervention Name(s)
Stent
Intervention Type
Device
Intervention Name(s)
Balloon
Primary Outcome Measure Information:
Title
The incidence of reocclusion between PTA alone and in combination with stent-placement groups
Time Frame
2 years
Secondary Outcome Measure Information:
Title
The survival between PTA alone and in combination with stent placement groups
Time Frame
2 years
Title
The incidence of procedure-related complications between PTA alone and in combination with stent placement groups
Time Frame
2 years
Title
The length of hospitalization between PTA alone and in combination with stent placement groups
Time Frame
2 years
Title
The symptom recurrence rate between PTA alone and in combination with stent placement groups
Time Frame
2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Informed consent. Age 18-75 years old. Budd-Chiari syndrome Child-Pugh score <13 points. Eligible for percutaneous recanalization. Exclusion Criteria: Pregnancy or lactation. Malignancy. HIV infection. Severe cardiac or lung diseases. Severe renal dysfunction (serum> 265.2 umol/l). Uncontrolled systemic infection. Allergic to contrast agents. Poor compliance. A prior history of percutaneous recanalization. Ineligible for percutaneous recanalization. Liver cirrhosis with severe portal hypertension-related complications. Acute liver failure. Progressive deterioration of liver function.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Guohong Han, MD
Organizational Affiliation
Xijing Hospital of Digestive Diseases, Fourth Military Medical University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Xijing Hospital of Digestive Diseases
City
Xi'an
State/Province
Shanxi
ZIP/Postal Code
710032
Country
China

12. IPD Sharing Statement

Citations:
PubMed Identifier
23143028
Citation
Han G, Qi X, Zhang W, He C, Yin Z, Wang J, Xia J, Xu K, Guo W, Niu J, Wu K, Fan D. Percutaneous recanalization for Budd-Chiari syndrome: an 11-year retrospective study on patency and survival in 177 Chinese patients from a single center. Radiology. 2013 Feb;266(2):657-67. doi: 10.1148/radiol.12120856. Epub 2012 Nov 9.
Results Reference
background
PubMed Identifier
24806162
Citation
Qi X, Han G. Images in clinical medicine. Abdominal-wall varices in the Budd-Chiari syndrome. N Engl J Med. 2014 May 8;370(19):1829. doi: 10.1056/NEJMicm1308567. No abstract available.
Results Reference
background
PubMed Identifier
23447059
Citation
Qi X, Wu F, Ren W, He C, Yin Z, Niu J, Bai M, Yang Z, Wu K, Fan D, Han G. Thrombotic risk factors in Chinese Budd-Chiari syndrome patients. An observational study with a systematic review of the literature. Thromb Haemost. 2013 May;109(5):878-84. doi: 10.1160/TH12-10-0784. Epub 2013 Feb 28.
Results Reference
background
PubMed Identifier
24694738
Citation
Qi X, Wu F, Fan D, Han G. Prevalence of thrombotic risk factors in Chinese Budd-Chiari syndrome patients: results of a prospective validation study. Eur J Gastroenterol Hepatol. 2014 May;26(5):576-7. doi: 10.1097/MEG.0000000000000056. No abstract available.
Results Reference
background
PubMed Identifier
24256572
Citation
Qi X, Guo W, He C, Zhang W, Wu F, Yin Z, Bai M, Niu J, Yang Z, Fan D, Han G. Transjugular intrahepatic portosystemic shunt for Budd-Chiari syndrome: techniques, indications and results on 51 Chinese patients from a single centre. Liver Int. 2014 Sep;34(8):1164-75. doi: 10.1111/liv.12355. Epub 2013 Nov 20.
Results Reference
background
PubMed Identifier
23692579
Citation
Qi X, Han G, Guo W, Yin Z, Fan D. Education and Imaging. Hepatobiliary and pancreatic: Budd-Chiari syndrome with infra-hepatic obstruction of inferior vena cava. J Gastroenterol Hepatol. 2013 Jun;28(6):905. doi: 10.1111/jgh.12228. No abstract available.
Results Reference
background
PubMed Identifier
31279647
Citation
Wang Q, Li K, He C, Yuan X, Luo B, Qi X, Guo W, Bai W, Yu T, Fan J, Wang Z, Yuan J, Li X, Zhu Y, Han N, Niu J, Lv Y, Liu L, Li J, Tang S, Guo S, Wang E, Xia D, Wang Z, Cai H, Wang J, Yin Z, Xia J, Fan D, Han G. Angioplasty with versus without routine stent placement for Budd-Chiari syndrome: a randomised controlled trial. Lancet Gastroenterol Hepatol. 2019 Sep;4(9):686-697. doi: 10.1016/S2468-1253(19)30177-3. Epub 2019 Jul 3.
Results Reference
derived

Learn more about this trial

Budd-Chiari Syndrome in China: Balloon Angioplasty Alone or Combined With Stent Placement?

We'll reach out to this number within 24 hrs